Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Fortress Biotech ($FBIO) is currently trading at a market cap below the value of its cash and shares in other publicly traded companies it owns. The company's preferred shares have a cumulative perpetual dividend that may be reactivated soon. One of their subsidiaries is approaching a PDUFA on September 30, which could lead to a PRV worth more than the current valuation of the company. Additionally, Fortress has funded and created multiple companies, such as Cyprium and Journey, and still holds significant stakes in them. The company's influence extends beyond being a passive shareholder, as they have the ability to steer strategy when needed.